203 related articles for article (PubMed ID: 21610701)
1. Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis.
Miest TS; Yaiw KC; Frenzke M; Lampe J; Hudacek AW; Springfeld C; von Messling V; Ungerechts G; Cattaneo R
Mol Ther; 2011 Oct; 19(10):1813-20. PubMed ID: 21610701
[TBL] [Abstract][Full Text] [Related]
2. Retargeted and Stealth-Modified Oncolytic Measles Viruses for Systemic Cancer Therapy in Measles Immune Patients.
Bah ES; Nace RA; Peng KW; Muñoz-Alía MÁ; Russell SJ
Mol Cancer Ther; 2020 Oct; 19(10):2057-2067. PubMed ID: 32847970
[TBL] [Abstract][Full Text] [Related]
3. MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum.
Muñoz-Alía MÁ; Nace RA; Tischer A; Zhang L; Bah ES; Auton M; Russell SJ
PLoS Pathog; 2021 Feb; 17(2):e1009283. PubMed ID: 33534834
[TBL] [Abstract][Full Text] [Related]
4. An immunocompetent murine model for oncolysis with an armed and targeted measles virus.
Ungerechts G; Springfeld C; Frenzke ME; Lampe J; Parker WB; Sorscher EJ; Cattaneo R
Mol Ther; 2007 Nov; 15(11):1991-7. PubMed ID: 17712331
[TBL] [Abstract][Full Text] [Related]
5. Measles virus glycoprotein-based lentiviral targeting vectors that avoid neutralizing antibodies.
Kneissl S; Abel T; Rasbach A; Brynza J; Schneider-Schaulies J; Buchholz CJ
PLoS One; 2012; 7(10):e46667. PubMed ID: 23071609
[TBL] [Abstract][Full Text] [Related]
6. Robust envelope exchange platform for oncolytic measles virus.
Neault S; Bossow S; Achard C; Bell JC; Diallo JS; Leber MF; Ungerechts G
J Virol Methods; 2022 Apr; 302():114487. PubMed ID: 35104497
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies.
Ong HT; Hasegawa K; Dietz AB; Russell SJ; Peng KW
Gene Ther; 2007 Feb; 14(4):324-33. PubMed ID: 17051248
[TBL] [Abstract][Full Text] [Related]
8. Canine distemper virus neutralization activity is low in human serum and it is sensitive to an amino acid substitution in the hemagglutinin protein.
Zhang X; Wallace OL; Domi A; Wright KJ; Driscoll J; Anzala O; Sanders EJ; Kamali A; Karita E; Allen S; Fast P; Gilmour J; Price MA; Parks CL
Virology; 2015 Aug; 482():218-24. PubMed ID: 25880113
[TBL] [Abstract][Full Text] [Related]
9. Graphene oxide arms oncolytic measles virus for improved effectiveness of cancer therapy.
Xia M; Luo D; Dong J; Zheng M; Meng G; Wu J; Wei J
J Exp Clin Cancer Res; 2019 Sep; 38(1):408. PubMed ID: 31533779
[TBL] [Abstract][Full Text] [Related]
10. Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination.
Baldo A; Galanis E; Tangy F; Herman P
Hum Vaccin Immunother; 2016 May; 12(5):1102-16. PubMed ID: 26631840
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model.
Mader EK; Maeyama Y; Lin Y; Butler GW; Russell HM; Galanis E; Russell SJ; Dietz AB; Peng KW
Clin Cancer Res; 2009 Dec; 15(23):7246-55. PubMed ID: 19934299
[TBL] [Abstract][Full Text] [Related]
12. Vaccinia virus recombinants expressing either the measles virus fusion or hemagglutinin glycoprotein protect dogs against canine distemper virus challenge.
Taylor J; Pincus S; Tartaglia J; Richardson C; Alkhatib G; Briedis D; Appel M; Norton E; Paoletti E
J Virol; 1991 Aug; 65(8):4263-74. PubMed ID: 1830113
[TBL] [Abstract][Full Text] [Related]
13. Vaccination of mice against canine distemper virus-induced encephalitis with vaccinia virus recombinants encoding measles or canine distemper virus antigens.
Wild TF; Bernard A; Spehner D; Villeval D; Drillien R
Vaccine; 1993; 11(4):438-44. PubMed ID: 8470428
[TBL] [Abstract][Full Text] [Related]
14. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR
Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845
[TBL] [Abstract][Full Text] [Related]
15. Measles Virus Hemagglutinin epitopes immunogenic in natural infection and vaccination are targeted by broad or genotype-specific neutralizing monoclonal antibodies.
Muñoz-Alía MA; Casasnovas JM; Celma ML; Carabaña J; Liton PB; Fernandez-Muñoz R
Virus Res; 2017 May; 236():30-43. PubMed ID: 28465158
[TBL] [Abstract][Full Text] [Related]
16. Chemovirotherapy of malignant melanoma with a targeted and armed oncolytic measles virus.
Kaufmann JK; Bossow S; Grossardt C; Sawall S; Kupsch J; Erbs P; Hassel JC; von Kalle C; Enk AH; Nettelbeck DM; Ungerechts G
J Invest Dermatol; 2013 Apr; 133(4):1034-42. PubMed ID: 23223133
[TBL] [Abstract][Full Text] [Related]
17. Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins.
Ayala-Breton C; Barber GN; Russell SJ; Peng KW
Hum Gene Ther; 2012 May; 23(5):484-91. PubMed ID: 22171635
[TBL] [Abstract][Full Text] [Related]
18. Development of measles virus-based shielded oncolytic vectors: suitability of other paramyxovirus glycoproteins.
Hudacek AW; Navaratnarajah CK; Cattaneo R
Cancer Gene Ther; 2013 Feb; 20(2):109-16. PubMed ID: 23306608
[TBL] [Abstract][Full Text] [Related]
19. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
[TBL] [Abstract][Full Text] [Related]
20. Functional and structural interactions between measles virus hemagglutinin and CD46.
Nussbaum O; Broder CC; Moss B; Stern LB; Rozenblatt S; Berger EA
J Virol; 1995 Jun; 69(6):3341-9. PubMed ID: 7745681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
